In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
On Monday, DexCom announced Stelo is now available for purchase without a prescription at Stelo.com.
Stelo is a small biosensor worn on the back of the upper arm.
It is specifically designed to provide the 125 million Americans with Type 2 diabetes who are not using insulin and those with prediabetes with personalized glucose insights sent directly to their smartphones.
These insights reveal how food, exercise, and sleep can affect ...
